Published in:
Open Access 01-12-2015 | Erratum
Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence
Published in: Breast Cancer Research | Issue 1/2015
Login to get accessExcerpt
During the editorial process preceding the publication of this article an error was introduced in the heading of “Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients.” This error was only noticed after publication of the final version. Specifically, both data-containing columns are labeled “Elafin Negative.” The data-containing column on the right should in fact be labeled “Elafin Positive (n = 482).” The corrected version can be found here (Table 1). Table 1 has also been updated in the original article to reflect the correct labeling of the columns.
Table 1
Univariate and multivariate analysis of elafin-positive cells in breast cancer patients
|
A. Univariate analysis, breast cancer (n = 793)
|
||||
|---|---|---|---|---|
|
Factors
|
Elafin negative (n = 311)
|
Elafin positive (n = 482)
|
p-value
|
|
|
Age of diagnosis, year
|
0.02
|
|||
|
Mean
|
55.5
|
53.5
|
||
|
Median (range)
|
55 (26–86)
|
52 (25–87)
|
||
|
Stage
|
<0.0001
|
|||
|
I
|
120 (38.7)
|
115 (24.0)
|
||
|
IIA
|
128 (41.3)
|
241 (50.2)
|
||
|
IIB
|
62 (20.0)
|
124 (25.8)
|
||
|
Unknown
|
1
|
2
|
||
|
ER
|
<0.0001
|
|||
|
Positive
|
266 (85.5)
|
280 (58.3)
|
||
|
Negative
|
45 (14.5)
|
200 (41.7)
|
||
|
Unknown
|
0
|
2
|
||
|
PR
|
<0.0001
|
|||
|
Positive
|
218 (70.1)
|
236 (49.2)
|
||
|
Negative
|
93 (29.9)
|
244 (50.8)
|
||
|
Unknown
|
0
|
2
|
||
|
HER-2
|
0.013
|
|||
|
Positive
|
42 (13.5)
|
98 (20.4)
|
||
|
Negative
|
269 (86.5)
|
383 (79.6)
|
||
|
Unknown
|
0
|
1
|
||
|
Grade
|
<0.0001
|
|||
|
I
|
41 (14.2)
|
31 (6.8)
|
||
|
II
|
186 (64.6)
|
197 (43.5)
|
||
|
III
|
61 (21.2)
|
225 (49.7)
|
||
|
Unknown
|
23
|
29
|
||
|
Tumor subtype
|
<0.0001
|
|||
|
Luminal A
|
185 (61.9)
|
158 (33.1)
|
||
|
Luminal B
|
45 (15.1)
|
94 (19.8)
|
||
|
Her2 positive
|
42 (14.0)
|
98 (20.7)
|
||
|
Triple negative
|
27 (9.0)
|
125 (26.4)
|
||
|
Unknown
|
12
|
7
|
||
|
Recurrence
|
<0.0001
|
|||
|
No
|
250 (80.9)
|
298 (62.3)
|
||
|
Yes
|
59 (19.1)
|
180 (37.7)
|
||
|
Unknown
|
2
|
4
|
||
|
B. Multivariate Cox proportional hazards analysis of clinicopathologic variables’ influence on breast cancer RFS in whole cohort (n = 793)
|
||||
|
Factor
|
HR
|
Se
|
P
|
95% CI
|
|
Stage
|
||||
|
I
|
referent
|
|||
|
IIA
|
1.67
|
0.31
|
0.005
|
1.17-2.39
|
|
IIB
|
2.41
|
0.47
|
<0.0001
|
1.65-3.52
|
|
Age
|
0.98
|
0.01
|
<0.0001
|
0.97-0.99
|
|
Elafin Positive
|
1.94
|
0.3
|
<0.0001
|
1.44-2.62
|